



## BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®

November 1, 2018

*More than 100 million Covered Lives Now Have Preferred Access to BELBUCA*

RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that a leading U.S. pharmacy benefit manager has added BELBUCA® (buprenorphine) buccal film to their national preferred formulary list effective November 1, 2018. BELBUCA is currently indicated in the U.S. for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

"We are very excited to have another major organization recognize the importance of patients having enhanced access to BELBUCA," said Herm Cukier, CEO of BDSI. "Inclusion by this leading pharmacy benefits manager adds an additional 24 million commercial lives with expanded access to the product, bringing the current total covered population, including both commercial and Medicare, with preferred access to more than 100 million. We remain committed to further expanding the number of patients having preferred access to BELBUCA as one of the key levers of continued product growth and success."

BELBUCA is the first and only Schedule III long-acting opioid that uses novel buccal film technology to deliver buprenorphine for appropriate patients living with chronic pain. Buprenorphine is a Schedule III controlled substance, meaning that it has been designated as having lower abuse potential than Schedule II drugs, a category which includes most opioid analgesics. Buprenorphine is a mu-opioid receptor partial agonist and a potent analgesic with a relatively long duration of action.

### **About BioDelivery Sciences International, Inc.**

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina.

For more information, please visit or follow us:

Internet: [www.bdsi.com](http://www.bdsi.com)  
Facebook: [Facebook.com/BioDeliverySI](https://www.facebook.com/BioDeliverySI)  
Twitter: @BioDeliverySI

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences. For full prescribing information and important safety information on BDSI products please visit [www.bdsi.com](http://www.bdsi.com) where the Company promptly posts press releases, SEC filings, and other important information or contact the Company at (800) 469-0261. For full prescribing and safety information on BELBUCA, please visit [www.belbuca.com](http://www.belbuca.com) and for full prescribing and safety information on BUNAVAIL, please visit [www.bunavail.com](http://www.bunavail.com).

### **Cautionary Note on Forward-Looking Statements**

This press release, the presentation described herein, and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. ("BDSI") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI's management and are subject to significant risks and uncertainties, including those detailed in the BDSI's filings with the Securities and Exchange Commission.

Actual results (including, without limitation, the anticipated benefits to the Company related to the preferred access to additional commercial lives as described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI's control). BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI®, BEMA®, ONSOLIS®, BUNAVAIL®, and BELBUCA® are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences, BUNAVAIL, and BELBUCA logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.

© 2018 BioDelivery Sciences International, Inc. All rights reserved.

### **Contacts**

Mary Coleman  
Vice President, Investor Relations and Corporate Communications  
BioDelivery Sciences International, Inc.  
919-582-9050  
[mcoleman@bdsi.com](mailto:mcoleman@bdsi.com)

Monique Kosse  
Managing Director  
LifeSci Advisors  
212-915-3820  
[monique@lifesciadvisors.co](mailto:monique@lifesciadvisors.co)



Source: BioDelivery Sciences International, Inc.